Abeona Therapeutics Announces Clinical Data Presentations at Upcoming Scientific Congresses
Abeona Therapeutics (Nasdaq: ABEO) announced two upcoming presentations of clinical data at scientific congresses in October 2021. The first presentation will showcase long-term wound healing and pain relief data from the Phase 1/2a EB-101 trial at the PeDRA Annual Conference on October 14-15, 2021. The second presentation will discuss interim results from the pivotal trial of investigational gene therapy ABO-102 in MPS IIIA at the ESGCT Congress from October 19-22, 2021. These events highlight Abeona's advancements in gene therapy for rare diseases.
- Presenting long-term data on EB-101 highlights effective treatment for chronic wounds in Recessive Dystrophic Epidermolysis Bullosa.
- Showcasing interim results for ABO-102 demonstrates progress in treating Sanfilippo Syndrome Type A.
- Forward-looking statements indicate uncertainties and risks related to clinical trial outcomes and regulatory approvals.
NEW YORK and CLEVELAND, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced two presentations of previously disclosed clinical data at upcoming scientific congresses in October 2021. The presentations include a poster presentation on the long-term wound healing and pain relief data from the Phase 1/2a EB-101 trial at the 2021 Pediatric Dermatology Research Alliance (PeDRA) Annual Conference, held virtually October 14-15, 2021; and an oral presentation on the pivotal trial of the Company’s investigational AAV-based gene therapy ABO-102 in MPS IIIA at the virtual 28th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), October 19-22, 2021.
Presentation details are as follows:
Event: 2021 PeDRA Annual Conference
Title: Long-Term Healing, Pain Reduction, and Patient-Reported Outcomes in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Following EB-101 Treatment of Large, Chronic Wounds
Poster Number: 45
Event: ESGCT 28th Annual Congress
Title: Interim Results of Transpher A, a Multicentre, Single-dose, Phase 1/2 Clinical Trial of ABO-102 Investigational Gene Therapy for Sanfilippo Syndrome Type A (Mucopolysaccharidosis IIIA)
Talk Number: INV38
Session: 4a
Date and Time: Thursday, October 21, 2021, 9:30 am CEST
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona’s clinical programs include EB-101, its investigational autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel investigational AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Abeona’s fully integrated gene and cell therapy cGMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and planned commercial production of AAV-based gene therapies. For more information, visit www.abeonatherapeutics.com.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “estimate,” “expect,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to the potential impacts of the COVID-19 pandemic on our business, operations, and financial condition, continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the outcome of any future meetings with the U.S. Food and Drug Administration or other regulatory agencies, the impact of competition, the ability to secure licenses for any technology that may be necessary to commercialize our products, the ability to achieve or obtain necessary regulatory approvals, the impact of changes in the financial markets and global economic conditions, risks associated with data analysis and reporting, and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q and other periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
FAQ
What clinical data will Abeona present in October 2021?
When and where will Abeona's data presentations take place?
What is the significance of the EB-101 trial data?
What does the interim result of ABO-102 signify for Abeona?
What risks does Abeona face regarding its clinical trials?
